Pfizer's Disappointing Financial Guidance

This chapter discusses Pfizer's recent financial guidance for 2024, which was below analyst expectations, leading to a decline in their stock price. It highlights the decline in sales of their COVID-19 products as a major factor in the lower revenue and profit forecasts. The chapter suggests that Pfizer's announcement was aimed at addressing their disappointing performance and setting realistic expectations.